共 46 条
[1]
Corado KC(2018)Two-drug regimens for treatment of naive HIV-1 infection and as maintenance therapy Drug Des Devel Ther 12 3731-3740
[2]
Caplan MR(2015)Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV Drug Des Devel Ther 9 3547-3555
[3]
Daar ES(2017)Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients BMC Infect Dis 17 215-77
[4]
Kandel CE(2015)Development and validation of stability-indicating HPLC method for simeltaneous determination of Lamivudine, tenofovir, and Dolutegravir in bulk and their tablet dosage form Future J Pharm Sci 1 73-1163
[5]
Walmsley SL(2015)Development and validation of UV spectrophotometric method for estimation of Dolutegravir sodium in tablet dosage form Malaysian J Anal Chem 19 1156-856
[6]
Maggiolo F(2011)Spectrophotometric determination of Lamivudine using chloranilic acid and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) Am J Anal Chem 2 849-419
[7]
Gulminetti R(2010)UV Spectrophotometric method for assay of the anti-retroviral agent Lamivudine in active pharmaceutical ingredient and in its tablet formulation J Young Pharm JYP 2 417-320
[8]
Pagnucco L(2016)High-performance liquid chromatographic and high-performance thin-layer chromatographic method for the quantitative estimation of Dolutegravir Sodium in bulk drug and pharmaceutical dosage form Sci Pharm 84 305-257
[9]
Digaetano M(2011)Development and validation of analytical method for the estimation of Lamivudine in rabbit plasma J Pharm Anal 1 251-55
[10]
Benatti S(2018)Development and validation of RP-HPLC method for the simultaneous estimation of Lamivudine, Tenofovir Alafenamide and Dolutegravir bulk and their combined dosage form Pharm Methods 9 49-127